| Methylated circulating tumor DNA in blood: power in cancer prognosis and response K Warton, KL Mahon, G Samimi Endocrine-related cancer 23 (3), R157-R171, 2016 | 174 | 2016 |
| Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response … L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ... Clinical genitourinary cancer 17 (1), 15-22, 2019 | 164 | 2019 |
| Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer HM Lin, L Castillo, KL Mahon, K Chiam, BY Lee, Q Nguyen, MJ Boyer, ... British journal of cancer 110 (10), 2462-2471, 2014 | 141 | 2014 |
| Pathways of chemotherapy resistance in castration-resistant prostate cancer KL Mahon, SM Henshall, RL Sutherland, LG Horvath Endocrine-related cancer 18 (4), R103-R123, 2011 | 113 | 2011 |
| Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate … KL Mahon, W Qu, J Devaney, C Paul, L Castillo, RJ Wykes, MD Chatfield, ... British journal of cancer 111 (9), 1802-1809, 2014 | 101 | 2014 |
| Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer M Kohli, W Tan, T Zheng, A Wang, C Montesinos, C Wong, P Du, S Jia, ... EBioMedicine 54, 2020 | 86 | 2020 |
| Management of colorectal cancer KGM Brown, MJ Solomon, K Mahon, S O’Shannassy Bmj 366, 2019 | 80 | 2019 |
| Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer KL Mahon, HM Lin, L Castillo, BY Lee, M Lee-Ng, MD Chatfield, K Chiam, ... British journal of cancer 112 (8), 1340-1348, 2015 | 70 | 2015 |
| A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer HM Lin, KL Mahon, JM Weir, PA Mundra, C Spielman, K Briscoe, ... International Journal of Cancer 141 (10), 2112-2120, 2017 | 57 | 2017 |
| Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer HM Lin, KL Mahon, C Spielman, H Gurney, G Mallesara, MR Stockler, ... British journal of cancer 116 (8), 1002-1011, 2017 | 57 | 2017 |
| Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer H Fettke, EM Kwan, MM Docanto, P Bukczynska, N Ng, LJK Graham, ... European urology 78 (2), 173-180, 2020 | 54 | 2020 |
| Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis–targeting agents in metastatic castration-resistant prostate cancer SQ To, EM Kwan, HC Fettke, A Mant, MM Docanto, L Martelotto, ... European urology 73 (6), 818-821, 2018 | 44 | 2018 |
| Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long‐term follow‐up J Grogan, R Gupta, KL Mahon, PD Stricker, AM Haynes, W Delprado, ... BJU international 120 (5), 651-658, 2017 | 44 | 2017 |
| Mainstream consent programs for genetic counseling in cancer patients: a systematic review T Scheinberg, A Young, H Woo, A Goodwin, KL Mahon, LG Horvath Asia‐Pacific Journal of Clinical Oncology 17 (3), 163-177, 2021 | 35 | 2021 |
| Serum free methylated glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data … KL Mahon, W Qu, HM Lin, C Spielman, D Cain, C Jacobs, MR Stockler, ... European urology 76 (3), 306-312, 2019 | 35 | 2019 |
| Evaluation of a mainstream model of genetic testing for men with prostate cancer T Scheinberg, A Goodwin, E Ip, A Linton, B Mak, DP Smith, MR Stockler, ... JCO Oncology Practice 17 (2), e204-e216, 2021 | 32 | 2021 |
| Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase HM Lin, B Mak, N Yeung, K Huynh, TG Meikle, NA Mellett, EM Kwan, ... EBioMedicine 72, 2021 | 24 | 2021 |
| Plasma cell–free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer EM Kwan, C Dai, H Fettke, C Hauser, MM Docanto, P Bukczynska, N Ng, ... JCO Precision Oncology 5, 622-637, 2021 | 24 | 2021 |
| Somatic mutations in salivary duct carcinoma and potential therapeutic targets TK Khoo, B Yu, JA Smith, AJ Clarke, PP Luk, CI Selinger, KL Mahon, ... Oncotarget 8 (44), 75893, 2017 | 21 | 2017 |
| A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer AY Zhang, JS Grogan, KL Mahon, K Rasiah, P Sved, DR Eisinger, ... Annals of Oncology 28 (8), 1903-1909, 2017 | 18 | 2017 |
